08 Feb Prescient Therapeutics
Steven Yatomi-Clarke, CEO
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies, including an innovative platform exclusively licensed from U.Penn and Oxford University called OmniCAR. OmniCAR provides an unprecedented level of control, safety, and flexibility to CAR-Immune cell therapies. Prescient’s Targeted therapies have unique MoAs targeting the RAS and AKT pathways and are in the clinic. Prescient is developing three programs with the OmniCAR platform. These include a CD33/CLL-1 dual antigen targeted OmniCAR for AML, a HER2 targeted OmniCAR for solid tumors, and a HER2/EGFRviii dual antigen targeting program for Glioblastoma Multiforme.